AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33970692
Drug: Early complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early complex decongestive therapy (CDT) started within 2 weeks after surgery for 30 minutes a day, for 2 weeks (5 days per week)
Trial: 32330433
Drug: Prednisolone (1mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1mg/kg/day for 24 weeks, tapering from week 9)
Trial: 34274496
Drug: Personalized antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antiplatelet therapy based on CYP2C19 genotype and urine 11‐dhTxB2 tests
Trial: 34621052
Drug: Aramchol 600
RxNorm normalized name: Aramchol
DrugBank: Aramchol (DB11860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aramchol 600 mg
Trial: 36199064
Drug: Metformin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin combined with dulaglutide (MET-DUL group)
Trial: 32060972
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual breakthrough dose)
Trial: 35701548
Drug: 94% ABV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 94% ABV alcohol (males: 1.0 ml/kg; females: 0.85 ml/kg)
Trial: 32727577
Drug: esaxerenone 5
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: esaxerenone 5 mg/day with amlodipine 2.5 mg (Study 2)
Trial: 32727577
Drug: esaxerenone 5
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: esaxerenone 5 mg/day with digoxin 0.25 mg/day (Study 3)
Trial: 33837943
Drug: 50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of landfill leachate (LL) dose plus irrigation water (IW)
Trial: 33837943
Drug: 200% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200% of landfill leachate (LL) dose plus irrigation water (IW)
Trial: 35590308
Drug: LIA (Local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA (Local Infiltration Analgesia) with ropivacaine, morphine, and betamethasone
Trial: 34372930
Drug: Preventative intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventative intervention comprising risk communication using an online risk calculator, counselling style adapted from motivational interviewing, and 12 weekly telephone goal reinforcement calls (3 months)
Trial: 34872927
Drug: Three-week language
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-week language therapy
Trial: 33393711
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 2.5 g EP/kg diet
Trial: 33393711
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 5.0 g EP/kg diet
Trial: 33393711
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 7.5 g EP/kg diet
Trial: 38479195
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion
Trial: 35131532
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) vaginal gel 3 g every 3 days for 30 days
Trial: 33652160
Drug: Vaginal isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal isosorbide mononitrate (40 mg, up to 3 doses)
Trial: 36074385
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg/kg/h)
Trial: 34101342
Drug: Ultrashort implants
RxNorm normalized name: UNDERPAD,BED ULTRASORB 23X24IN #MSC82100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrashort implants (5.5 mm)
Trial: 34101342
Drug: Standard-length implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-length implants (10 mm)
Trial: 39623757
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies
Trial: 38502425
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone
Trial: 39334205
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids
Trial: 35758258
Drug: BMS-986120 75
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986120 75 mg
Trial: 35758258
Drug: BMS-986120 180
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986120 180 mg
Trial: 35758258
Drug: BMS-986120 ≥10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986120 ≥10 mg for 7 days
Trial: 35758258
Drug: BMS-986120 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986120 (various doses)
Trial: 32423618
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids
Trial: 35554022
Drug: Nomogram based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram based on significant indices (age, tumor type, type of surgery, radiation therapy)
Trial: 32449174
Drug: Ravulizumab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (administered every 8 weeks)
Trial: 32449174
Drug: Eculizumab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (administered every 2 weeks)
Trial: 36217131
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg, once daily)
Trial: 36217131
Drug: Budesonide/formoterol (160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (160/4.5 μg, one puff, twice daily)
Trial: 32453453
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure reduction with intravenous nicardipine
Trial: 34314516
Drug: CAPABLE program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPABLE program (full-tested dose)
Trial: 34314516
Drug: CAPABLE program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPABLE program (decreased dose)
Trial: 34778952
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment
Trial: 33637001
Drug: Reboxetine (noradrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (noradrenaline reuptake inhibitor)
Trial: 39673452
Drug: Dupilumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab treatment
Trial: 39165177
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment
Trial: 35202621
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg) three times weekly for 3 months along with standard treatment
Trial: 35977072
Drug: LY2409021 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2409021 (100 mg single dose)
Trial: 32939849
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil therapy (administered two weeks before surgery)
Trial: 34738855
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg/day for one week, then titrated to 60 mg/day for 12 weeks)
Trial: 34738855
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule daily for one week, then two capsules daily for 12 weeks)
Trial: 34028826
Drug: Probiotics (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (one capsule/day for 30 days)
Trial: 34028826
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule/day for 30 days)
Trial: 35790574
Drug: Adalimumab (HUMIRA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (HUMIRA) injection
Trial: 34190716
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg PO daily for 2 weeks
Trial: 35857037
Drug: Acipimox and
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox and conventional treatment
Trial: 35702828
Drug: Sublingual buprenorphine/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine/naloxone (8 mg/2 mg to 24 mg/6 mg per day; flexible take-home dosing)
Trial: 35702828
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (≈60-120 mg/day; closely supervised)
Trial: 35702828
Drug: Sublingual buprenorphine/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine/naloxone
Trial: 32349893
Drug: Açaí juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Açaí juice (200 mL/day for 4 weeks)
Trial: 32349893
Drug: Juçara juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juçara juice (200 mL/day for 4 weeks)
Trial: 33108244
Drug: rhG-CSF combined
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhG-CSF combined with minimal-dose Dec (G-Dec group: 100 µg/m2 of rhG-CSF on days 0-5 and 5 mg/m2 of Dec on days 1-5)
Trial: 33108244
Drug: no intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no intervention (non-G-Dec group)
Trial: 37623203
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg)
Trial: 32591498
Drug: Six repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six repeated ketamine infusions
Trial: 33607775
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection combined with sodium nitroprusside
Trial: 35620919
Drug: α-difluoromethylornithine (DFMO)
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: α-difluoromethylornithine (DFMO) administered orally at a dosage of 500 mg/m2/day for up to 5 years.
Trial: 35620919
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) administered orally for up to 5 years.
Trial: 32271671
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (CT+E)
Trial: 34614209
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (E)
Trial: 33601378
Drug: Emollient plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient plus cream (EC; Dermoflan®) applied once daily for 2 months
Trial: 33044990
Drug: Tobacco Cessation
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco Cessation on Prescription (TCP)
Trial: 34303447
Drug: Community Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Care (CC)
Trial: 33663235
Drug: Conventional glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose-lowering therapy
Trial: 33724542
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) 50 mg/week
Trial: 33662902
Drug: Lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective ventilation (LPV) with tidal volume 6 ml/kg PBW + PEEP 7 cmH2O
Trial: 33662902
Drug: Nonprotective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprotective ventilation (control group) with tidal volume 9 ml/kg PBW without PEEP
Trial: 34310276
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Pain (CBT‐P)
Trial: 36343068
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional physical therapy treatment)
Trial: 36410806
Drug: Standard dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysate magnesium concentration of 0.50 mmol/L
Trial: 35279301
Drug: Imported dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported dental implants (control group)
Trial: 33200812
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the morning for 6 weeks
Trial: 33200812
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 10 mg rosuvastatin and ezetimibe administered in the evening for 6 weeks
Trial: 33200812
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of the drug
Trial: 33200812
Drug: Morning vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning vs Evening drug administration
Trial: 35101110
Drug: Pars plana
RxNorm normalized name: Planatus occidentalis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas, and intravitreal aflibercept.
Trial: 35101110
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept monotherapy.
Trial: 33738656
Drug: Two courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Trial: 33738656
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of DCF (70 mg/m2 intravenous docetaxel and 70 mg/m2 intravenous cisplatin on day 1, and a continuous 700 mg/m2 fluorouracil infusion for 5 days) every 3 weeks
Trial: 32723670
Drug: SPN-812 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 100 mg/day
Trial: 34608329
Drug: Islatravir 62
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 62 mg
Trial: 37869523
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment
Trial: 35142582
Drug: Daratumumab-based triplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab-based triplet therapies (VGPR or better)
Trial: 33216196
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 10 mg/kg/day, orally
Trial: 35981821
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation)
Trial: 34338759
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (SAPT)
Trial: 33411910
Drug: 12 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g/day of fructooligosaccharide (FOS) for 3 months
Trial: 34690144
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg
Trial: 32207575
Drug: 25 mg/ml
RxNorm normalized name: hemin 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/ml tranexamic acid (TXA)
Trial: 36765312
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control condition)
Trial: 37661604
Drug: Cryomodulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryomodulation treatment (10-min controlled cooling)
Trial: 37661604
Drug: Cryomodulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryomodulation treatment
Trial: 34241762
Drug: 17-estradiol (E2)
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17-estradiol (E2) (10 µg/g body weight)
Trial: 34241762
Drug: Blank (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank (no injection)
Trial: 34962574
Drug: MAO-B inhibitor
RxNorm normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAO-B inhibitor
Trial: 34962574
Drug: COMT inhibitor
RxNorm normalized name: levodopa, decarboxylase inhibitor and COMT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMT inhibitor
Trial: 34962574
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist vs MAO-B inhibitors
Trial: 34962574
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist and MAO-B inhibitors
Trial: 33085647
Drug: Cerebellar intermittent
RxNorm normalized name: Sus scrofa cerebellum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebellar intermittent theta burst stimulation (iTBS), 10-day treatment
Trial: 34689142
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without treatment)
Trial: 32266595
Drug: Independent risk
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent risk factors identified: age, race, T stage, N stage, M stage, surgery, radiotherapy, chemotherapy, marital status.
Trial: 34836235
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of PXN
Trial: 34784246
Drug: Lumbar spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar spine treatment only (LBO group)
Trial: 34784246
Drug: Lumbar spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar spine and hip treatments (LBH group)
Trial: 35737076
Drug: Robot-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-Assisted Therapy (RT)
Trial: 34293643
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT)
Trial: 35984478
Drug: CGM-guided insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGM-guided insulin adjustment
Trial: 32950830
Drug: Montelukast combined
RxNorm normalized name: montelukast, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast combined with intranasal mometasone furoate (Group I)
Trial: 32950830
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate alone (Group II)
Trial: 36148627
Drug: Milky lotions
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milky lotions containing mevalonolactone (MVL)
Trial: 35060943
Drug: Psyllium (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (6 g/d)
Trial: 32827122
Drug: NHF 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHF 20 L/min
Trial: 32827122
Drug: NHF 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHF 50 L/min
Trial: 35526858
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g/day)
Trial: 34118065
Drug: Intensified support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified support by clinical pharmacologists/pharmacists for patients and treatment team
Trial: 34118065
Drug: Advanced medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced medication reviews performed by clinical pharmacologists/pharmacists
Trial: 34118065
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticancer drug regimen
Trial: 34118065
Drug: Drug-drug or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-drug or drug-food interactions
Trial: 32349070
Drug: Preoperative angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative angiotensin system inhibitors
Trial: 32349070
Drug: Postoperative angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative angiotensin system inhibitors
Trial: 32349070
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no angiotensin system inhibitors preoperatively)
Trial: 32349070
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no angiotensin system inhibitors postoperatively)
Trial: 33065080
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual antiplatelet therapy (DAPT; ticagrelor and aspirin) followed by 23-month ticagrelor monotherapy
Trial: 34528897
Drug: iGAM app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: iGAM app intervention group (photographed gums weekly for 8 weeks)
Trial: 33787834
Drug: Revacept 160
RxNorm normalized name: Revacept
DrugBank: PR-15 (DB06037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revacept 160 mg
Trial: 39018515
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy